Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • Graduate Research Assistant, Biostatistics, University of North Carolina - Chapel Hill 1996 - 2003
  • Ph.D., University of North Carolina - Chapel Hill 2003
  • Graduate Research Assistant, Computer Sciences, University of North Carolina - Chapel Hill 1994 - 1996
• 

  Duke Appointment History

  • Professor of Biostatistics and Bioinformatics, Biostatistics & Bioinformatics, Basic Science Departments 2020
  • Associate Professor of Biostatistics and Bioinformatics, Biostatistics & Bioinformatics, Basic Science Departments 2012 - 2019
  • Assistant Professor of Biostatistics and Bioinformatics, Biostatistics & Bioinformatics, Basic Science Departments 2007 - 2012
  • Assistant Research Professor of Biostatistics and Bioinformatics, Biostatistics & Bioinformatics, Basic Science Departments 2004 - 2007
  • Instructor, Temporary of Biostatistics and Bioinformatics, Biostatistics & Bioinformatics, Basic Science Departments 2003
• Recognition
• 

  Awards & Honors

  • ASA Fellow. American Statistical Association. 2021
• Expertise
• 

  Global Scholarship

  • Expertise

    • China (Country) 
• Research
• 

  Selected Grants

  • Alliance NCORP Research Base awarded by Alliance for Clinical Trials in Oncology (NCTN) 2020 - 2025
  • Anti-PD1 in combination with an inhibitor of PCSK9 to increase MHC class I molecule expression on tumor cells as immunotherapy for NSCLC awarded by Department of Defense 2021 - 2024
  • Cell-Free DNA for Diagnosis of Malignancy, Genetic Mutations and Prognosis in Lung Cancer Related Pleural Effusions awarded by Department of Defense 2020 - 2022
  • Alliance for Clinical Trials in Oncology awarded by Brigham and Women's Hospital 2019 - 2022
  • Alliance Statistical and Data Management Center - Clinical Trials in Oncology awarded by Mayo Clinic 2019 - 2022
  • Alliance Foundation Trials - IT Infrastructure - SOW awarded by Alliance Foundation Trials, LLC 2021
  • AFT - 42 Trials 5b awarded by Alliance Foundation Trials, LLC 2020 - 2021
  • AFT-09 and AFT-16 Trials (5a) awarded by Alliance Foundation Trials, LLC 2020 - 2021
  • AFT-46 Trials 5c awarded by Alliance Foundation Trials, LLC 2020 - 2021
  • 2020 Duke - Industry Statistical Symposium (DISS) awarded by Boehringer Ingelheim Pharmaceuticals, Inc. 2020 - 2021
  • Empower treatment effects evaluation of randomized clinical trials for elderly patients with integrated real-world data awarded by North Carolina State University 2020 - 2021
  • Alliance Foundation Trials - IT Infrastructure - SOW awarded by Alliance Foundation Trials, LLC 2020
  • AFT SOW 3 awarded by Alliance Foundation Trials, LLC 2019 - 2020
  • Alliance NCORP Research Base awarded by Mayo Clinic 2014 - 2020
  • Administrative Core awarded by University of North Carolina - Chapel Hill 2015 - 2020
  • Innovative Biomarker-Integrated Clinical Trial Design and Analysis awarded by University of North Carolina - Chapel Hill 2015 - 2020
  • Methods for Discovery and Analysis of Dynamic Treatment Regimes awarded by University of North Carolina - Chapel Hill 2015 - 2020
  • Alliance Foundation Trials - IT Infrastructure awarded by Alliance Foundation Trials, LLC 2018 - 2019
  • AFT SOW 2 awarded by Alliance Foundation Trials, LLC 2018 - 2019
  • Alliance for Clinical Trials in Oncology awarded by Mayo Clinic 2017 - 2019
  • Alliance for Clinical Trials in Oncology awarded by Brigham and Women's Hospital 2014 - 2019
  • Alliance for Clinical Trials in Oncology awarded by Mayo Clinic 2017 - 2018
  • National Clinical Trials Network - Network Group Statistics and DMCs awarded by Mayo Clinic 2014 - 2017
  • Translational meta-analysis for elderly lung cancer patients awarded by National Institutes of Health 2013 - 2016
  • Cancer and Leukemia Group B Statistical Center awarded by National Institutes of Health 1982 - 2010
  • Semiparametric ROC Curve Regression for Cancer Screening Studies awarded by National Institutes of Health 2007 - 2010
• Publications & Artistic Works
• 

  Selected Publications

  • Books

    • George, Stephen L., Xiaofei Wang, and Herbert Pang. Cancer Clinical Trials Current and Controversial Issues in Design and Analysis. CRC Press, 2016.

  • Academic Articles

    • Isaacs, James, Aaron C. Tan, Brent A. Hanks, Xiaofei Wang, Kouros Owzar, James E. Herndon, Scott J. Antonia, Steven Piantadosi, and Mustafa Khasraw. “Clinical Trials with Biologic Primary Endpoints in Immuno-oncology: Concepts and Usage.” Clin Cancer Res, July 26, 2021. https://doi.org/10.1158/1078-0432.CCR-21-1593.
       Full Text  Link to Item
    • Le-Rademacher, Jennifer, and Xiaofei Wang. “Time-To-Event Data: An Overview and Analysis Considerations.” J Thorac Oncol 16, no. 7 (July 2021): 1067–74. https://doi.org/10.1016/j.jtho.2021.04.004.
       Full Text  Link to Item
    • Wahidi, Momen M., Kevin Davidson, Scott Shofer, Kamran Mahmood, George Cheng, Coral Giovacchini, Claudia Jones, et al. “Pilot Study of the Performance of 19-G Needle in Endobronchial Ultrasound-guided Transbronchial Aspiration for the Diagnosis and Testing of Molecular Markers in Lung Cancer.” J Bronchology Interv Pulmonol 28, no. 3 (July 1, 2021): 209–14. https://doi.org/10.1097/LBR.0000000000000736.
       Full Text  Link to Item
    • Jacobs, Corbin D., Kurren Mehta, Junheng Gao, Xiaofei Wang, Joseph K. Salama, Chris R. Kelsey, and Jordan A. Torok. “Nomogram Predicting Overall Survival Benefit of Stereotactic Ablative Radiotherapy for Early-Stage Non-Small Cell Lung Cancer.” Clin Lung Cancer, June 24, 2021. https://doi.org/10.1016/j.cllc.2021.06.008.
       Full Text  Link to Item
    • Bogart, Jeffrey A., Xiaofei Wang, Gregory A. Masters, Junheng Gao, Ritsuko Komaki, Laurie E. Gaspar, John V. Heymach, et al. “Short Communication: Interim toxicity analysis for patients with limited stage small cell lung cancer (LSCLC) treated on CALGB 30610 (Alliance) / RTOG 0538.” Lung Cancer 156 (June 2021): 68–71. https://doi.org/10.1016/j.lungcan.2021.04.016.
       Full Text  Link to Item
    • Tong, Betty C., Lin Gu, Xiaofei Wang, Dennis A. Wigle, Joseph D. Phillips, David H. Harpole, Jacob A. Klapper, Thomas Sporn, Neal E. Ready, and Thomas A. D’Amico. “Perioperative outcomes of pulmonary resection after neoadjuvant pembrolizumab in patients with non-small cell lung cancer.” J Thorac Cardiovasc Surg, April 9, 2021. https://doi.org/10.1016/j.jtcvs.2021.02.099.
       Full Text  Link to Item
    • Wang, Xiaofei, Steven Piantadosi, Jennifer Le-Rademacher, and Sumithra J. Mandrekar. “Statistical Considerations for Subgroup Analyses.” J Thorac Oncol 16, no. 3 (March 2021): 375–80. https://doi.org/10.1016/j.jtho.2020.12.008.
       Full Text  Link to Item
    • Wong, Melisa L., Junheng Gao, Gita Thanarajasingam, Jeff A. Sloan, Amylou C. Dueck, Paul J. Novotny, Aminah Jatoi, et al. “Expanding Beyond Maximum Grade: Chemotherapy Toxicity over Time by Age and Performance Status in Advanced Non-Small Cell Lung Cancer in CALGB 9730 (Alliance A151729).” Oncologist 26, no. 3 (March 2021): e435–44. https://doi.org/10.1002/onco.13527.
       Full Text  Link to Item
    • Stinchcombe, Thomas E., Robert C. Doebele, Xiaofei Wang, David E. Gerber, Leora Horn, and D Ross Camidge. “Preliminary Clinical and Molecular Analysis Results From a Single-Arm Phase 2 Trial of Brigatinib in Patients With Disease Progression After Next-Generation ALK Tyrosine Kinase Inhibitors in Advanced ALK+ NSCLC.” J Thorac Oncol 16, no. 1 (January 2021): 156–61. https://doi.org/10.1016/j.jtho.2020.09.018.
       Full Text  Link to Item
    • Le-Rademacher, Jennifer, Camden Lopez, Eric Wolfe, Nathan R. Foster, Sumithra J. Mandrekar, Xiaofei Wang, Rajiv Kumar, Alex Adjei, and Aminah Jatoi. “Weight loss over time and survival: a landmark analysis of 1000+ prospectively treated and monitored lung cancer patients.” J Cachexia Sarcopenia Muscle 11, no. 6 (December 2020): 1501–8. https://doi.org/10.1002/jcsm.12625.
       Full Text  Link to Item
    • Bueno, Raphael, William G. Richards, David H. Harpole, Karla V. Ballman, Ming-Sound Tsao, Zhengming Chen, Xiaofei Wang, et al. “Multi-Institutional Prospective Validation of Prognostic mRNA Signatures in Early Stage Squamous Lung Cancer (Alliance).” J Thorac Oncol 15, no. 11 (November 2020): 1748–57. https://doi.org/10.1016/j.jtho.2020.07.005.
       Full Text  Link to Item
    • Dudek, Arkadiusz Z., Xiaofei Wang, Lin Gu, Stephanie Duong, Thomas E. Stinchcombe, Robert Kratzke, Hossein Borghaei, Everett E. Vokes, and Hedy L. Kindler. “Randomized Study of Maintenance Pemetrexed Versus Observation for Treatment of Malignant Pleural Mesothelioma: CALGB 30901.” Clin Lung Cancer 21, no. 6 (November 2020): 553-561.e1. https://doi.org/10.1016/j.cllc.2020.06.025.
       Full Text  Link to Item
    • Wang, Ting, Xiaofei Wang, Stephen L. George, and Haibo Zhou. “Design and analysis of biomarker-integrated clinical trials with adaptive threshold detection and flexible patient enrichment.” J Biopharm Stat 30, no. 6 (November 1, 2020): 1060–76. https://doi.org/10.1080/10543406.2020.1832110.
       Full Text  Link to Item
    • Wang, Fan, Richard L. Schilsky, David Page, Robert M. Califf, Kei Cheung, Xiaofei Wang, and Herbert Pang. “Development and Validation of a Natural Language Processing Tool to Generate the CONSORT Reporting Checklist for Randomized Clinical Trials.” Jama Netw Open 3, no. 10 (October 1, 2020): e2014661. https://doi.org/10.1001/jamanetworkopen.2020.14661.
       Full Text  Link to Item
    • Yan, Kang K., Xiaofei Wang, Wendy W. T. Lam, Varut Vardhanabhuti, Anne W. M. Lee, and Herbert H. Pang. “Radiomics analysis using stability selection supervised component analysis for right-censored survival data.” Comput Biol Med 124 (September 2020): 103959. https://doi.org/10.1016/j.compbiomed.2020.103959.
       Full Text  Link to Item
    • Wu, Yuan, Xiaofei Wang, Jiaxing Lin, Beilin Jia, and Kouros Owzar. “Predictive accuracy of markers or risk scores for interval censored survival data.” Stat Med 39, no. 18 (August 15, 2020): 2437–46. https://doi.org/10.1002/sim.8547.
       Full Text  Link to Item
    • Zhang, Jianrong, Meagan R. Pilar, Xiaofei Wang, Jingxia Liu, Herbert Pang, Ross C. Brownson, Graham A. Colditz, Wenhua Liang, and Jianxing He. “Endpoint surrogacy in oncology Phase 3 randomised controlled trials.” Br J Cancer 123, no. 3 (August 2020): 333–34. https://doi.org/10.1038/s41416-020-0896-5.
       Full Text  Link to Item
    • Jacobs, Corbin D., Junheng Gao, Xiaofei Wang, Jeffrey M. Clarke, Betty Tong, Neal E. Ready, Gita Suneja, Chris R. Kelsey, and Jordan A. Torok. “Definitive Radiotherapy for Inoperable Stage IIB Non-small-cell Lung Cancer: Patterns of Care and Comparative Effectiveness.” Clin Lung Cancer 21, no. 3 (May 2020): 238–46. https://doi.org/10.1016/j.cllc.2019.10.005.
       Full Text  Link to Item
    • Cao, Xiaowen, Apar Kishor Ganti, Thomas Stinchcombe, Melisa L. Wong, James C. Ho, Chen Shen, Yingzhou Liu, Jeffery Crawford, Herbert Pang, and Xiaofei Wang. “Predicting risk of chemotherapy-induced severe neutropenia: A pooled analysis in individual patients data with advanced lung cancer.” Lung Cancer 141 (March 2020): 14–20. https://doi.org/10.1016/j.lungcan.2020.01.004.
       Full Text  Link to Item
    • Giovacchini, Coral X., Edward R. Kessler, Christopher M. Merrick, Junheng Gao, Xiaofei Wang, Momen M. Wahidi, Scott L. Shofer, George Z. Cheng, and Kamran Mahmood. “Clinical and radiographic predictors of successful therapeutic bronchoscopy for the relief of malignant central airway obstruction.” Bmc Pulm Med 19, no. 1 (November 21, 2019): 219. https://doi.org/10.1186/s12890-019-0987-3.
       Full Text  Link to Item
    • Stinchcombe, Thomas E., Pasi A. Jänne, Xiaofei Wang, Erin M. Bertino, Jared Weiss, Lyudmila Bazhenova, Lin Gu, et al. “Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial.” Jama Oncol 5, no. 10 (October 1, 2019): 1448–55. https://doi.org/10.1001/jamaoncol.2019.1847.
       Full Text  Link to Item
    • Ganti, Apar Kishor, Xiaofei Wang, Thomas E. Stinchcombe, Yinpeng Wang, Jeffrey Bradley, Harvey J. Cohen, Karen Kelly, et al. “Clinical prognostic model for older patients with advanced non-small cell lung cancer.” J Geriatr Oncol 10, no. 4 (July 2019): 555–59. https://doi.org/10.1016/j.jgo.2019.02.007.
       Full Text  Link to Item
    • Zhang, Jianrong, Wenhua Liang, Hengrui Liang, Xiaofei Wang, and Jianxing He. “Endpoint surrogacy in oncological randomized controlled trials with immunotherapies: a systematic review of trial-level and arm-level meta-analyses.” Ann Transl Med 7, no. 11 (June 2019): 244. https://doi.org/10.21037/atm.2019.04.72.
       Full Text  Link to Item
    • Hamy, Anne-Sophie, Sandrine Tury, Xiaofei Wang, Junheng Gao, Jean-Yves Pierga, Sylvie Giacchetti, Etienne Brain, et al. “Celecoxib With Neoadjuvant Chemotherapy for Breast Cancer Might Worsen Outcomes Differentially by COX-2 Expression and ER Status: Exploratory Analysis of the REMAGUS02 Trial.” J Clin Oncol 37, no. 8 (March 10, 2019): 624–35. https://doi.org/10.1200/JCO.18.00636.
       Full Text  Link to Item
    • Schild, Steven E., Wen Fan, Thomas E. Stinchcombe, Everett E. Vokes, Suresh S. Ramalingam, Jeffrey D. Bradley, Karen Kelly, Herbert H. Pang, and Xiaofei Wang. “Toxicity Related to Radiotherapy Dose and Targeting Strategy: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Locally Advanced Non-Small Cell Lung Cancer.” J Thorac Oncol 14, no. 2 (February 2019): 298–303. https://doi.org/10.1016/j.jtho.2018.09.021.
       Full Text  Link to Item
    • Stinchcombe, Thomas E., Wen Fan, Steven E. Schild, Everett E. Vokes, Jeff Bogart, Quynh-Thu Le, Charles R. Thomas, et al. “A pooled analysis of individual patient data from National Clinical Trials Network clinical trials of concurrent chemoradiotherapy for limited-stage small cell lung cancer in elderly patients versus younger patients.” Cancer 125, no. 3 (February 1, 2019): 382–90. https://doi.org/10.1002/cncr.31813.
       Full Text  Link to Item
    • Gao, Hao, Chris R. Kelsey, John Boyle, Tianyi Xie, Suzanne Catalano, Xiaofei Wang, and Fang-Fang Yin. “Impact of Esophageal Motion on Dosimetry and Toxicity With Thoracic Radiation Therapy.” Technol Cancer Res Treat 18 (January 2019): 1533033819849073. https://doi.org/10.1177/1533033819849073.
       Full Text  Open Access Copy  Link to Item
    • Wang, Xiaofei, Fangfang Bai, Herbert Pang, and Stephen L. George. “Bias-adjusted Kaplan-Meier survival curves for marginal treatment effect in observational studies.” J Biopharm Stat 29, no. 4 (2019): 592–605. https://doi.org/10.1080/10543406.2019.1633659.
       Full Text  Link to Item
    • Wang, Ting, Xiaofei Wang, Haibo Zhou, Jianwen Cai, and Stephen L. George. “Auxiliary variable-enriched biomarker-stratified design.” Stat Med 37, no. 30 (December 30, 2018): 4610–35. https://doi.org/10.1002/sim.7938.
       Full Text  Link to Item
    • Altorki, Nasser K., Xiaofei Wang, Dennis Wigle, Lin Gu, Gail Darling, Ahmad S. Ashrafi, Rodney Landrenau, et al. “Perioperative mortality and morbidity after sublobar versus lobar resection for early-stage non-small-cell lung cancer: post-hoc analysis of an international, randomised, phase 3 trial (CALGB/Alliance 140503).” Lancet Respir Med 6, no. 12 (December 2018): 915–24. https://doi.org/10.1016/S2213-2600(18)30411-9.
       Full Text  Link to Item
    • Yang, Chi-Fu Jeffrey, Derek Y. Chan, Shivani A. Shah, Babatunde A. Yerokun, Xiaofei F. Wang, Thomas A. D’Amico, Mark F. Berry, and David H. Harpole. “Long-term Survival After Surgery Compared With Concurrent Chemoradiation for Node-negative Small Cell Lung Cancer.” Ann Surg 268, no. 6 (December 2018): 1105–12. https://doi.org/10.1097/SLA.0000000000002287.
       Full Text  Link to Item
    • Li, Zhiguo, Xiaofei Wang, Yuan Wu, and Kouros Owzar. “Sample size calculation for studies with grouped survival data.” Stat Med 37, no. 27 (November 30, 2018): 3904–17. https://doi.org/10.1002/sim.7847.
       Full Text  Open Access Copy  Link to Item
    • Kinsey, Emily, Elizabeth Ajazi, Xiaofei Wang, Mary Ann Mayzie Johnston, and Jeffrey Crawford. “Predictors of Physical and Functional Loss in Advanced-Stage Lung Cancer Patients Receiving Platinum Chemotherapy.” J Thorac Oncol 13, no. 9 (September 2018): 1294–1301. https://doi.org/10.1016/j.jtho.2018.05.029.
       Full Text  Link to Item
    • Schild, Steven E., Herbert H. Pang, Wen Fan, Thomas E. Stinchcombe, Everett E. Vokes, Suresh S. Ramalingam, Jeffrey D. Bradley, Karen Kelly, and Xiaofei Wang. “Exploring Radiotherapy Targeting Strategy and Dose: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Stage III NSCLC.” J Thorac Oncol 13, no. 8 (August 2018): 1171–82. https://doi.org/10.1016/j.jtho.2018.04.011.
       Full Text  Link to Item
    • Urbanic, James J., Xiaofei Wang, Jeffrey A. Bogart, Thomas E. Stinchcombe, Lydia Hodgson, Steven E. Schild, Lyudmila Bazhenova, Olwen Hahn, Ravi Salgia, and Everett E. Vokes. “Phase 1 Study of Accelerated Hypofractionated Radiation Therapy With Concurrent Chemotherapy for Stage III Non-Small Cell Lung Cancer: CALGB 31102 (Alliance).” Int J Radiat Oncol Biol Phys 101, no. 1 (May 1, 2018): 177–85. https://doi.org/10.1016/j.ijrobp.2018.01.046.
       Full Text  Link to Item
    • Yang, Chi-Fu Jeffrey, Frances McSherry, Nicholas R. Mayne, Xiaofei Wang, Mark F. Berry, Betty Tong, David H. Harpole, et al. “Surgical Outcomes After Neoadjuvant Chemotherapy and Ipilimumab for Non-Small Cell Lung Cancer.” Ann Thorac Surg 105, no. 3 (March 2018): 924–29. https://doi.org/10.1016/j.athoracsur.2017.09.030.
       Full Text  Link to Item
    • Nasution, Marlina D., and Xiaofei Wang. “Statistical issues and advances in cancer precision medicine research.” J Biopharm Stat 28, no. 2 (2018): 215–16. https://doi.org/10.1080/10543406.2017.1405013.
       Full Text  Link to Item
    • Wang, Xiaofei, Jingzhu Zhou, Ting Wang, and Stephen L. George. “On Enrichment Strategies for Biomarker Stratified Clinical Trials.” J Biopharm Stat 28, no. 2 (2018): 292–308. https://doi.org/10.1080/10543406.2017.1379532.
       Full Text  Open Access Copy  Link to Item
    • Yi, John S., Neal Ready, Patrick Healy, Chelsae Dumbauld, Robyn Osborne, Mark Berry, Debra Shoemaker, et al. “Immune Activation in Early-Stage Non-Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab.” Clin Cancer Res 23, no. 24 (December 15, 2017): 7474–82. https://doi.org/10.1158/1078-0432.CCR-17-2005.
       Full Text  Link to Item
    • Yang, Chi-Fu Jeffrey, Hanghang Wang, Arvind Kumar, Xiaofei Wang, Matthew G. Hartwig, Thomas A. D’Amico, and Mark F. Berry. “Impact of Timing of Lobectomy on Survival for Clinical Stage IA Lung Squamous Cell Carcinoma.” Chest 152, no. 6 (December 2017): 1239–50. https://doi.org/10.1016/j.chest.2017.07.032.
       Full Text  Link to Item
    • Stinchcombe, Thomas E., Ying Zhang, Everett E. Vokes, Joan H. Schiller, Jeffrey D. Bradley, Karen Kelly, Walter J. Curran, et al. “Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies.” J Clin Oncol 35, no. 25 (September 1, 2017): 2885–92. https://doi.org/10.1200/JCO.2016.71.4758.
       Full Text  Link to Item
    • Yao, Xiaoxin I., Xiaofei Wang, Paul J. Speicher, E Shelley Hwang, Perry Cheng, David H. Harpole, Mark F. Berry, Deborah Schrag, and Herbert H. Pang. “Reporting and Guidelines in Propensity Score Analysis: A Systematic Review of Cancer and Cancer Surgical Studies.” J Natl Cancer Inst 109, no. 8 (August 1, 2017). https://doi.org/10.1093/jnci/djw323.
       Full Text  Link to Item
    • Yerokun, Babatunde A., Chi-Fu Jeffrey Yang, Brian C. Gulack, Xuechan Li, Michael S. Mulvihill, Lin Gu, Xiaofei Wang, et al. “A national analysis of wedge resection versus stereotactic body radiation therapy for stage IA non-small cell lung cancer.” J Thorac Cardiovasc Surg 154, no. 2 (August 2017): 675-686.e4. https://doi.org/10.1016/j.jtcvs.2017.02.065.
       Full Text  Link to Item
    • Edelman, Martin J., Xiaofei Wang, Lydia Hodgson, Richard T. Cheney, Maria Q. Baggstrom, Sachdev P. Thomas, Ajeet Gajra, et al. “Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance).” J Clin Oncol 35, no. 19 (July 1, 2017): 2184–92. https://doi.org/10.1200/JCO.2016.71.3743.
       Full Text  Link to Item
    • Kohman, Leslie J., Lin Gu, Nasser Altorki, Ernest Scalzetti, Linda J. Veit, Jason M. Wallen, and Xiaofei Wang. “Biopsy first: Lessons learned from Cancer and Leukemia Group B (CALGB) 140503.” J Thorac Cardiovasc Surg 153, no. 6 (June 2017): 1592–97. https://doi.org/10.1016/j.jtcvs.2016.12.045.
       Full Text  Link to Item
    • Baggstrom, Maria Q., Mark A. Socinski, Xiaofei F. Wang, Lin Gu, Thomas E. Stinchcombe, Martin J. Edelman, Sherman Baker, et al. “Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study-CALGB 30607 (Alliance).” J Thorac Oncol 12, no. 5 (May 2017): 843–49. https://doi.org/10.1016/j.jtho.2017.01.022.
       Full Text  Link to Item
    • Edelman, M. J., X. Wang, L. Hodgson, R. T. Cheney, M. Q. Baggstrom, T. Sachdev, A. Gajra, et al. “Final Results of a Phase 3 Trial of Celecoxib (C) in Addition to Standard Chemotherapy for Advanced Non-Small Cell Lung Cancer With COX- 2 Overexpression: CALGB 30801 (Alliance).” Int J Radiat Oncol Biol Phys 98, no. 1 (May 1, 2017): 220–21. https://doi.org/10.1016/j.ijrobp.2017.01.038.
       Full Text  Link to Item
    • Augert, Arnaud, Qing Zhang, Breanna Bates, Min Cui, Xiaofei Wang, Gary Wildey, Afshin Dowlati, and David MacPherson. “Small Cell Lung Cancer Exhibits Frequent Inactivating Mutations in the Histone Methyltransferase KMT2D/MLL2: CALGB 151111 (Alliance).” J Thorac Oncol 12, no. 4 (April 2017): 704–13. https://doi.org/10.1016/j.jtho.2016.12.011.
       Full Text  Link to Item
    • Cox, Morgan L., Chi-Fu Jeffrey Yang, Paul J. Speicher, Kevin L. Anderson, Zachary W. Fitch, Lin Gu, Robert Patrick Davis, et al. “The Role of Extent of Surgical Resection and Lymph Node Assessment for Clinical Stage I Pulmonary Lepidic Adenocarcinoma: An Analysis of 1991 Patients.” J Thorac Oncol 12, no. 4 (April 2017): 689–96. https://doi.org/10.1016/j.jtho.2017.01.003.
       Full Text  Link to Item
    • Hwang, E Shelley, and Xiaofei Wang. “Value of Propensity Score Matching to Study Surgical Outcomes.” Ann Surg 265, no. 3 (March 2017): 457–58. https://doi.org/10.1097/SLA.0000000000002125.
       Full Text  Link to Item
    • Wang, Xiaofei, Xiaoyi Wang, Lydia Hodgson, Stephen L. George, Daniel J. Sargent, Nate R. Foster, Apar Kishor Ganti, et al. “Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials.” Oncologist 22, no. 2 (February 2017): 189–98. https://doi.org/10.1634/theoncologist.2016-0121.
       Full Text  Link to Item
    • Torok, Jordan A., Lin Gu, Daniel J. Tandberg, Xiaofei Wang, David H. Harpole, Chris R. Kelsey, and Joseph K. Salama. “Patterns of Distant Metastases After Surgical Management of Non-Small-cell Lung Cancer.” Clin Lung Cancer 18, no. 1 (January 2017): e57–70. https://doi.org/10.1016/j.cllc.2016.06.011.
       Full Text  Link to Item
    • Wang, Xiao-Fei, Yi-Tong Zhu, Jia-Jia Wang, Da-Xiong Zeng, Chuan-Yong Mu, Yan-Bin Chen, Wei Lei, Ye-Han Zhu, and Jian-An Huang. “The prognostic value of interleukin-17 in lung cancer: A systematic review with meta-analysis based on Chinese patients.” Plos One 12, no. 9 (2017): e0185168. https://doi.org/10.1371/journal.pone.0185168.
       Full Text  Link to Item
    • Yang, Chi-Fu Jeffrey, Derek Y. Chan, Xiaofei Wang, Thomas A. D’Amico, David H. Harpole, and Mark F. Berry. “Reply to T.-H. Wang et al.” J Clin Oncol 35, no. 1 (January 2017): 118–20. https://doi.org/10.1200/JCO.2016.68.6980.
       Full Text  Link to Item
    • Pang, Herbert H., Xiaofei Wang, Thomas E. Stinchcombe, Melisa L. Wong, Perry Cheng, Apar Kishor Ganti, Daniel J. Sargent, et al. “Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012.” J Clin Oncol 34, no. 33 (November 20, 2016): 3992–99. https://doi.org/10.1200/JCO.2016.67.7088.
       Full Text  Link to Item
    • De Ruysscher, D., B. Lueza, C. Le Péchoux, D. H. Johnson, M. O’Brien, N. Murray, S. Spiro, et al. “Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis.” Ann Oncol 27, no. 10 (October 2016): 1818–28. https://doi.org/10.1093/annonc/mdw263.
       Full Text  Link to Item
    • Huang, Aimi, Rong Li, Jikai Zhao, Xiaofei Wang, Bo Jin, Yanjie Niu, Jie Zhang, Liyan Jiang, and Baohui Han. “Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors combined with chemotherapy in first-line treatment in an advanced non-small cell lung cancer patient with EGFR sensitive mutation.” Thorac Cancer 7, no. 5 (September 2016): 614–18. https://doi.org/10.1111/1759-7714.12364.
       Full Text  Link to Item
    • Boyer, Matthew J., Lin Gu, Xiaofei Wang, Chris R. Kelsey, David S. Yoo, Mark W. Onaitis, Frank R. Dunphy, Jeffrey Crawford, Neal E. Ready, and Joseph K. Salama. “Toxicity of definitive and post-operative radiation following ipilimumab in non-small cell lung cancer.” Lung Cancer 98 (August 2016): 76–78. https://doi.org/10.1016/j.lungcan.2016.05.014.
       Full Text  Link to Item
    • Zhu, Zhaoyin, Xiaofei Wang, Paramita Saha-Chaudhuri, Andrzej S. Kosinski, and Stephen L. George. “Time-dependent classification accuracy curve under marker-dependent sampling.” Biom J 58, no. 4 (July 2016): 974–92. https://doi.org/10.1002/bimj.201500171.
       Full Text  Link to Item
    • Martin, Linda W., Jonathan D’Cunha, Xiaofei Wang, Debra Herzan, Lin Gu, Naif Abraham, Todd L. Demmy, et al. “Detection of Occult Micrometastases in Patients With Clinical Stage I Non-Small-Cell Lung Cancer: A Prospective Analysis of Mature Results of CALGB 9761 (Alliance).” J Clin Oncol 34, no. 13 (May 1, 2016): 1484–91. https://doi.org/10.1200/JCO.2015.63.4543.
       Full Text  Link to Item
    • Yang, Chi-Fu Jeffrey, Arvind Kumar, Brian C. Gulack, Michael S. Mulvihill, Matthew G. Hartwig, Xiaofei Wang, Thomas A. D’Amico, and Mark F. Berry. “Long-term outcomes after lobectomy for non-small cell lung cancer when unsuspected pN2 disease is found: A National Cancer Data Base analysis.” J Thorac Cardiovasc Surg 151, no. 5 (May 2016): 1380–88. https://doi.org/10.1016/j.jtcvs.2015.12.028.
       Full Text  Link to Item
    • Yang, Chi-Fu Jeffrey, Derek Y. Chan, Paul J. Speicher, Brian C. Gulack, Xiaofei Wang, Matthew G. Hartwig, Mark W. Onaitis, et al. “Role of Adjuvant Therapy in a Population-Based Cohort of Patients With Early-Stage Small-Cell Lung Cancer.” J Clin Oncol 34, no. 10 (April 1, 2016): 1057–64. https://doi.org/10.1200/JCO.2015.63.8171.
       Full Text  Link to Item
    • Speicher, Paul J., Brian R. Englum, Asvin M. Ganapathi, Xiaofei Wang, Matthew G. Hartwig, Thomas A. D’Amico, and Mark F. Berry. “Traveling to a High-volume Center is Associated With Improved Survival for Patients With Esophageal Cancer.” Ann Surg, March 15, 2016. https://doi.org/10.1097/SLA.0000000000001702.
       Full Text  Link to Item
    • Salama, Joseph K., Lin Gu, Xiaofei Wang, Herbert H. Pang, Jeffrey A. Bogart, Jeffrey Crawford, Steven E. Schild, Everett E. Vokes, and Neal E. Ready. “Positive Interaction between Prophylactic Cranial Irradiation and Maintenance Sunitinib for Untreated Extensive-Stage Small Cell Lung Cancer Patients After Standard Chemotherapy: A Secondary Analysis of CALGB 30504 (ALLIANCE).” J Thorac Oncol 11, no. 3 (March 2016): 361–69. https://doi.org/10.1016/j.jtho.2015.11.001.
       Full Text  Link to Item
    • Wang, Xiaofei, and Mark F. Berry. “Risk calculators are useful but....” J Thorac Cardiovasc Surg 151, no. 3 (March 2016): 706–7. https://doi.org/10.1016/j.jtcvs.2015.09.058.
       Full Text  Link to Item
    • Pang, Herbert, and Xiaofei Wang. “Statistical aspect of translational and correlative studies in clinical trials.” Chin Clin Oncol 5, no. 1 (February 2016): 11. https://doi.org/10.3978/j.issn.2304-3865.2014.07.04.
       Full Text  Link to Item
    • Speicher, Paul J., Lin Gu, Brian C. Gulack, Xiaofei Wang, Thomas A. D’Amico, Matthew G. Hartwig, and Mark F. Berry. “Sublobar Resection for Clinical Stage IA Non-small-cell Lung Cancer in the United States.” Clin Lung Cancer 17, no. 1 (January 2016): 47–55. https://doi.org/10.1016/j.cllc.2015.07.005.
       Full Text  Link to Item
    • Xia, Fang, Stephen L. George, and Xiaofei Wang. “A Multi-state Model for Designing Clinical Trials for Testing Overall Survival Allowing for Crossover after Progression.” Stat Biopharm Res 8, no. 1 (2016): 12–21. https://doi.org/10.1080/19466315.2015.1093539.
       Full Text  Link to Item
    • Clarke, Jeffrey M., Xiaofei Wang, and Neal E. Ready. “Surrogate clinical endpoints to predict overall survival in non-small cell lung cancer trials-are we in a new era?” Transl Lung Cancer Res 4, no. 6 (December 2015): 804–8. https://doi.org/10.3978/j.issn.2218-6751.2015.05.03.
       Full Text  Link to Item
    • Gulack, Brian C., Chi-Fu Jeffrey Yang, Paul J. Speicher, James M. Meza, Lin Gu, Xiaofei Wang, Thomas A. D’Amico, Matthew G. Hartwig, and Mark F. Berry. “The impact of tumor size on the association of the extent of lymph node resection and survival in clinical stage I non-small cell lung cancer.” Lung Cancer 90, no. 3 (December 2015): 554–60. https://doi.org/10.1016/j.lungcan.2015.10.011.
       Full Text  Link to Item
    • Yang, Chi-Fu Jeffrey, Brian C. Gulack, Lin Gu, Paul J. Speicher, Xiaofei Wang, David H. Harpole, Mark W. Onaitis, Thomas A. D’Amico, Mark F. Berry, and Matthew G. Hartwig. “Adding radiation to induction chemotherapy does not improve survival of patients with operable clinical N2 non-small cell lung cancer.” J Thorac Cardiovasc Surg 150, no. 6 (December 2015): 1484–92. https://doi.org/10.1016/j.jtcvs.2015.06.062.
       Full Text  Link to Item
    • Zhao, J., Y. Zhao, T. Qiu, W. Jiao, Y. Xuan, X. Wang, Y. Wang, and Y. Luo. “Quality of life and survival after II stage nonsmall cell carcinoma surgery: Video-assisted thoracic surgery versus thoracotomy lobectomy.” Indian J Cancer 52 Suppl 2 (December 2015): e130–33. https://doi.org/10.4103/0019-509X.172510.
       Full Text  Link to Item
    • Speicher, P. J., X. Wang, B. R. Englum, A. M. Ganapathi, B. Yerokun, M. G. Hartwig, T. A. D’Amico, and M. F. Berry. “Induction chemoradiation therapy prior to esophagectomy is associated with superior long-term survival for esophageal cancer.” Dis Esophagus 28, no. 8 (November 2015): 788–96. https://doi.org/10.1111/dote.12285.
       Full Text  Link to Item
    • Wang, Xiaofei, Lin Gu, Ying Zhang, Daniel J. Sargent, William Richards, Apar Kishor Ganti, Jeffery Crawford, et al. “Validation of survival prognostic models for non-small-cell lung cancer in stage- and age-specific groups.” Lung Cancer 90, no. 2 (November 2015): 281–87. https://doi.org/10.1016/j.lungcan.2015.08.007.
       Full Text  Link to Item
    • Salama, Joseph K., Lin Gu, Xiaofei Wang, Jeffrey Bogart, Jeffrey Crawford, Steven Schild, Neal Ready, and Everett Vokes. “PCI Survival Improvement for Extensive Stage SCLC Limited to Patients on Maintenance Systemic Therapy: A Secondary Analysis of CALGB 30504.” Journal of Thoracic Oncology 10, no. 9 (September 1, 2015): S401–S401.
       Link to Item
    • Foster, Nathan R., Lindsay A. Renfro, Steven E. Schild, Mary W. Redman, Xiaofei F. Wang, Suzanne E. Dahlberg, Keyue Ding, et al. “Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer.” J Thorac Oncol 10, no. 7 (July 2015): 1099–1106. https://doi.org/10.1097/JTO.0000000000000548.
       Full Text  Link to Item
    • Speicher, Paul J., Lin Gu, Xiaofei Wang, Matthew G. Hartwig, Thomas A. D’Amico, and Mark F. Berry. “Adjuvant Chemotherapy After Lobectomy for T1-2N0 Non-Small Cell Lung Cancer: Are the Guidelines Supported?” J Natl Compr Canc Netw 13, no. 6 (June 2015): 755–61. https://doi.org/10.6004/jnccn.2015.0090.
       Full Text  Link to Item
    • Nwogu, Chukwumere E., Jonathan D’Cunha, Herbert Pang, Lin Gu, Xiaofei Wang, William G. Richards, Linda J. Veit, et al. “VATS lobectomy has better perioperative outcomes than open lobectomy: CALGB 31001, an ancillary analysis of CALGB 140202 (Alliance).” Ann Thorac Surg 99, no. 2 (February 2015): 399–405. https://doi.org/10.1016/j.athoracsur.2014.09.018.
       Full Text  Link to Item
    • Lilenbaum, Rogerio, Michael Samuels, Xiaofei Wang, Feng Ming Kong, Pasi A. Jänne, Gregory Masters, Sreedhar Katragadda, et al. “A phase II study of induction chemotherapy followed by thoracic radiotherapy and erlotinib in poor-risk stage III non-small-cell lung cancer: results of CALGB 30605 (Alliance)/RTOG 0972 (NRG).” J Thorac Oncol 10, no. 1 (January 2015): 143–47. https://doi.org/10.1097/JTO.0000000000000347.
       Full Text  Link to Item
    • Heist, Rebecca S., Xiaofei Wang, Lydia Hodgson, Gregory A. Otterson, Thomas E. Stinchcombe, Leena Gandhi, Miguel A. Villalona-Calero, et al. “CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer.” J Thorac Oncol 9, no. 2 (February 2014): 214–21. https://doi.org/10.1097/JTO.0000000000000071.
       Full Text  Link to Item
    • Berry, Mark F., Mathias Worni, Xiaofei Wang, David H. Harpole, Thomas A. D’Amico, and Mark W. Onaitis. “Sleeve lobectomy for non-small cell lung cancer with N1 nodal disease does not compromise survival.” Ann Thorac Surg 97, no. 1 (January 2014): 230–35. https://doi.org/10.1016/j.athoracsur.2013.09.016.
       Full Text  Link to Item
    • Jiao, W., Y. Zhao, X. Wang, and J. Zhao. “Video-assisted thoracoscopic left upper lobe sleeve lobectomy combined with pulmonary arterioplasty via two-port approach.” Journal of Thoracic Disease 6, no. 12 (January 1, 2014): 1813–15. https://doi.org/10.3978/j.issn.2072-1439.2014.11.09.
       Full Text
    • Ma, Qianli, Deruo Liu, Yongqing Guo, Bin Shi, Yanchu Tian, Zhiyi Song, Zhenrong Zhang, Bingsheng Ge, Xiaofei Wang, and Thomas A. D’Amico. “Surgical techniques and results of the pulmonary artery reconstruction for patients with central non-small cell lung cancer.” J Cardiothorac Surg 8 (December 1, 2013): 219. https://doi.org/10.1186/1749-8090-8-219.
       Full Text  Link to Item
    • Ma, Qianli, Deruo Liu, Yongqing Guo, Bin Shi, Zhiyi Song, Yan-chu Tian, Bingsheng Ge, Xiaofei Wang, and Thomas A. D. Amico. “SURGICAL TECHNIQUES AND RESULTS OF RECONSTRUCTION OF THE PULMONARY ARTERY FOR PATIENTS WITH CENTRAL NON-SMALL CELL LUNG CANCER.” Journal of Thoracic Oncology 8 (November 1, 2013): S217–S217.
       Link to Item
    • Pang, Herbert, Lydia Hodgson, Robert Kratzke, Jeffrey Crawford, Hedy Kindler, Everett Vokes, and Xiaofei Wang. “VALIDATION OF THE CALGB AND EORTC PROGNOSTIC MODELS FOR MESOTHELIOMA BASED ON MULTIPLE CALGB TRIALS (ALLIANCE).” Journal of Thoracic Oncology 8 (November 1, 2013): S934–35.
       Link to Item
    • Boylan, Alice M., Xiaofei F. Wang, Richard Ko, Patricia M. Watson, Lin Gu, David Harpole, Raphael Bueno, Rosemary Kelly, Leslie Kohman, and Robert Kratzke. “Detection of human telomerase reverse transcriptase mRNA in cells obtained by lavage of the pleura is not associated with worse outcome in patients with stage I/II non-small cell lung cancer: results from Cancer and Leukemia Group B 159902.” J Thorac Cardiovasc Surg 146, no. 1 (July 2013): 206–11. https://doi.org/10.1016/j.jtcvs.2012.08.059.
       Full Text  Link to Item
    • Jaklitsch, Michael T., Lin Gu, Todd Demmy, David H. Harpole, Thomas A. D’Amico, Robert J. McKenna, Mark J. Krasna, et al. “Prospective phase II trial of preresection thoracoscopic mediastinal restaging after neoadjuvant therapy for IIIA (N2) non-small cell lung cancer: results of CALGB Protocol 39803.” J Thorac Cardiovasc Surg 146, no. 1 (July 2013): 9–16. https://doi.org/10.1016/j.jtcvs.2012.12.069.
       Full Text  Link to Item
    • Wang, Xiaofei, Junling Ma, and Stephen L. George. “ROC curve estimation under test-result-dependent sampling.” Biostatistics 14, no. 1 (January 2013): 160–72. https://doi.org/10.1093/biostatistics/kxs020.
       Full Text  Link to Item
    • Demmy, Todd L., Lin Gu, Jack E. Burkhalter, Eric M. Toloza, Thomas A. D’Amico, Susan Sutherland, Xiaofei Wang, et al. “Optimal management of malignant pleural effusions (results of CALGB 30102).” J Natl Compr Canc Netw 10, no. 8 (August 2012): 975–82. https://doi.org/10.6004/jnccn.2012.0102.
       Full Text  Link to Item
    • Chen, J., X. Wang, D. Yang, and B. Fan. “Nonparametric modeling auxiliary covariates in random coefficient models.” Communications in Statistics: Simulation and Computation 41, no. 8 (July 2, 2012): 1271–81. https://doi.org/10.1080/03610918.2011.594535.
       Full Text
    • Jänne, Pasi A., Xiaofei Wang, Mark A. Socinski, Jeffrey Crawford, Thomas E. Stinchcombe, Lin Gu, Marzia Capelletti, et al. “Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial.” J Clin Oncol 30, no. 17 (June 10, 2012): 2063–69. https://doi.org/10.1200/JCO.2011.40.1315.
       Full Text  Link to Item
    • Edelman, Martin J., Lydia Hodgson, Xiaofei Wang, Robert A. Kratzke, and Everett E. Vokes. “Cyclooxygenase-2 (COX-2) as a predictive marker for the use of COX-2 inhibitors in advanced non-small-cell lung cancer.” J Clin Oncol 30, no. 16 (June 1, 2012): 2019–20. https://doi.org/10.1200/JCO.2011.41.4581.
       Full Text  Link to Item
    • Jahan, Thierry, Lin Gu, Robert Kratzke, Arkadiusz Dudek, Gregory A. Otterson, Xiaofei Wang, Mark Green, Everett E. Vokes, and Hedy Lee Kindler. “Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107).” Lung Cancer 76, no. 3 (June 2012): 393–96. https://doi.org/10.1016/j.lungcan.2011.11.014.
       Full Text  Link to Item
    • Xue, D. Q., C. Qian, L. Yang, and X. F. Wang. “Risk factors for surgical site infections after breast surgery: a systematic review and meta-analysis.” Eur J Surg Oncol 38, no. 5 (May 2012): 375–81. https://doi.org/10.1016/j.ejso.2012.02.179.
       Full Text  Link to Item
    • Edelman, Martin J., Lydia Hodgson, Paula Y. Rosenblatt, Robert H. Christenson, Everett E. Vokes, Xiaofei Wang, and Robert Kratzke. “CYFRA 21-1 as a prognostic and predictive marker in advanced non-small-cell lung cancer in a prospective trial: CALGB 150304.” J Thorac Oncol 7, no. 4 (April 2012): 649–54. https://doi.org/10.1097/JTO.0b013e31824a8db0.
       Full Text  Link to Item
    • Schroen, Anneke T., Gina R. Petroni, Hongkun Wang, Monika J. Thielen, Robert Gray, Jacqueline Benedetti, Xiaofei F. Wang, et al. “Achieving sufficient accrual to address the primary endpoint in phase III clinical trials from U.S. Cooperative Oncology Groups.” Clin Cancer Res 18, no. 1 (January 1, 2012): 256–62. https://doi.org/10.1158/1078-0432.CCR-11-1633.
       Full Text  Link to Item
    • Wang, Xiaofei, Junling Ma, Stephen George, and Haibo Zhou. “Estimation of AUC or Partial AUC under Test-Result-Dependent Sampling.” Stat Biopharm Res 4, no. 4 (January 1, 2012): 313–23. https://doi.org/10.1080/19466315.2012.692514.
       Full Text  Link to Item
    • Kawaguchi, A., G. G. Koch, and X. Wang. “Stratified multivariate Mann-Whitney estimators for the comparison of two treatments with randomization based covariance adjustment.” Statistics in Biopharmaceutical Research 3, no. 2 (December 1, 2011): 217–31. https://doi.org/10.1198/sbr.2010.10007.
       Full Text
    • Salama, Joseph K., Thomas E. Stinchcombe, Lin Gu, Xiaofei Wang, Karen Morano, Jeffrey A. Bogart, Jeffrey C. Crawford, et al. “Pulmonary toxicity in Stage III non-small cell lung cancer patients treated with high-dose (74 Gy) 3-dimensional conformal thoracic radiotherapy and concurrent chemotherapy following induction chemotherapy: a secondary analysis of Cancer and Leukemia Group B (CALGB) trial 30105.” Int J Radiat Oncol Biol Phys 81, no. 4 (November 15, 2011): e269–74. https://doi.org/10.1016/j.ijrobp.2011.01.056.
       Full Text  Link to Item
    • Edelman, Martin J., Lydia Hodgson, Xiaofei Wang, Robert Christenson, Scott Jewell, Everett Vokes, and Robert Kratzke. “Serum vascular endothelial growth factor and COX-2/5-LOX inhibition in advanced non-small cell lung cancer: Cancer and Leukemia Group B 150304.” J Thorac Oncol 6, no. 11 (November 2011): 1902–6. https://doi.org/10.1097/JTO.0b013e31822a7383.
       Full Text  Link to Item
    • Masters, Gregory A., Xiaofei Wang, Lydia Hodgson, Thomas Shea, Everett Vokes, and Mark Green. “A phase II trial of high dose carboplatin and paclitaxel with G-CSF and peripheral blood stem cell support followed by surgery and/or chest radiation in patients with stage III non-small cell lung cancer: CALGB 9531.” Lung Cancer 74, no. 2 (November 2011): 258–63. https://doi.org/10.1016/j.lungcan.2011.03.015.
       Full Text  Link to Item
    • Schroen, Anneke T., Gina R. Petroni, Hongkun Wang, Monika J. Thielen, Daniel Sargent, Jacqueline K. Benedetti, Walter M. Cronin, et al. “Challenges to accrual predictions to phase III cancer clinical trials: a survey of study chairs and lead statisticians of 248 NCI-sponsored trials.” Clin Trials 8, no. 5 (October 2011): 591–600. https://doi.org/10.1177/1740774511419683.
       Full Text  Link to Item
    • Wu, Yougui, and Xiaofei Wang. “Optimal weight in estimating and comparing areas under the receiver operating characteristic curve using longitudinal data.” Biom J 53, no. 5 (September 2011): 764–78. https://doi.org/10.1002/bimj.201100033.
       Full Text  Link to Item
    • Govindan, Ramaswamy, Jeffrey Bogart, Thomas Stinchcombe, Xiaofei Wang, Lydia Hodgson, Robert Kratzke, Jennifer Garst, Timothy Brotherton, and Everett E. Vokes. “Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407.” J Clin Oncol 29, no. 23 (August 10, 2011): 3120–25. https://doi.org/10.1200/JCO.2010.33.4979.
       Full Text  Link to Item
    • Janne, Pasi A., Xiaofei Wang, Mark A. Socinski, Jeffrey Crawford, Lin Gu, Marzia Capelletti, Martin J. Edelman, et al. “OUTCOME OF ADVANCED NSCLC PATIENTS WITH EGFR EXON 19 AND 21 MUTATIONS TREATED WITH ERLOTINIB (E) ALONE OR IN COMBINATION WITH CARBOPLATIN/PACLITAXEL (CP) IN CALGB 30406.” Journal of Thoracic Oncology 6, no. 6 (June 1, 2011): S447–48.
       Link to Item
    • Dubey, Sarita, Pasi A. Jänne, Lee Krug, Herbert Pang, Xiaofei Wang, Robin Heinze, Colleen Watt, et al. “A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307.” J Thorac Oncol 5, no. 10 (October 2010): 1655–61. https://doi.org/10.1097/JTO.0b013e3181ec18db.
       Full Text  Link to Item
    • Ready, Neal, Pasi A. Jänne, Jeffrey Bogart, Thomas Dipetrillo, Jennifer Garst, Stephen Graziano, Lin Gu, et al. “Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial.” J Thorac Oncol 5, no. 9 (September 2010): 1382–90. https://doi.org/10.1097/JTO.0b013e3181eba657.
       Full Text  Link to Item
    • Schroen, Anneke T., Gina R. Petroni, Hongkun Wang, Robert Gray, Xiaofei F. Wang, Walter Cronin, Daniel J. Sargent, et al. “Preliminary evaluation of factors associated with premature trial closure and feasibility of accrual benchmarks in phase III oncology trials.” Clin Trials 7, no. 4 (August 2010): 312–21. https://doi.org/10.1177/1740774510374973.
       Full Text  Link to Item
    • Graziano, Stephen L., Lin Gu, Xiaofei Wang, Arthur H. Tatum, Robin T. Vollmer, Gary M. Strauss, Robert Kratzke, et al. “Prognostic significance of mucin and p53 expression in stage IB non-small cell lung cancer: a laboratory companion study to CALGB 9633.” J Thorac Oncol 5, no. 6 (June 2010): 810–17. https://doi.org/10.1097/jto.0b013e3181d89f95.
       Full Text  Link to Item
    • Wang, Xiaofei, and Haibo Zhou. “Design and inference for cancer biomarker study with an outcome and auxiliary-dependent subsampling.” Biometrics 66, no. 2 (June 2010): 502–11. https://doi.org/10.1111/j.1541-0420.2009.01280.x.
       Full Text  Link to Item
    • Partridge, Ann H., Laura Archer, Alice B. Kornblith, Julie Gralow, Debjani Grenier, Edith Perez, Antonio C. Wolff, et al. “Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104.” J Clin Oncol 28, no. 14 (May 10, 2010): 2418–22. https://doi.org/10.1200/JCO.2009.26.4671.
       Full Text  Link to Item
    • Aupérin, Anne, Cecile Le Péchoux, Estelle Rolland, Walter J. Curran, Kiyoyuki Furuse, Pierre Fournel, Jose Belderbos, et al. “Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer.” J Clin Oncol 28, no. 13 (May 1, 2010): 2181–90. https://doi.org/10.1200/JCO.2009.26.2543.
       Full Text  Link to Item
    • Bogart, Jeffrey A., Lydia Hodgson, Stephen L. Seagren, A William Blackstock, Xiaofei Wang, Robert Lenox, Andrew T. Turrisi, et al. “Phase I study of accelerated conformal radiotherapy for stage I non-small-cell lung cancer in patients with pulmonary dysfunction: CALGB 39904.” J Clin Oncol 28, no. 2 (January 10, 2010): 202–6. https://doi.org/10.1200/JCO.2009.25.0753.
       Full Text  Link to Item
    • Wang, Xiaofei, Yougui Wu, and Haibo Zhou. “Outcome- and auxiliary-dependent subsampling and its statistical inference.” J Biopharm Stat 19, no. 6 (November 2009): 1132–50. https://doi.org/10.1080/10543400903243025.
       Full Text  Link to Item
    • Lilenbaum, Rogerio, Xiaofei Wang, Lin Gu, Jeffrey Kirshner, Keith Lerro, and Everett Vokes. “Randomized phase II trial of docetaxel plus cetuximab or docetaxel plus bortezomib in patients with advanced non-small-cell lung cancer and a performance status of 2: CALGB 30402.” J Clin Oncol 27, no. 27 (September 20, 2009): 4487–91. https://doi.org/10.1200/JCO.2009.22.7066.
       Full Text  Link to Item
    • D’Cunha, Jonathan, Xiaofei Wang, Shawn S. Groth, Robin T. Vollmer, Naif Z. Abraham, Debra L. Herzan, Lin Gu, et al. “The impact of occult micrometastases on survival following resection of stage I non-small cell lung cancer: final analysis of CALGB 9761.” Journal of Thoracic Oncology 4, no. 9 (September 1, 2009): S576–S576.
       Link to Item
    • Govindan, Ramaswamy, Jeff Bogart, Xiaofei Wang, Lydia Hodgson, Robert A. Kratzke, and Everett E. Vokes. “A phase II study of pemetrexed, carboplatin and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small cell lung cancer: CALGB 30407.” Journal of Thoracic Oncology 4, no. 9 (September 1, 2009): S371–72.
       Link to Item
    • Govindan, Ramaswamy, Xiaofei Wang, Maria Q. Baggstrom, Susan Burdette-Radoux, Lydia Hodgson, Everett E. Vokes, Mark R. Green, and Mark R. Cancer and Leukemia Group B. “A phase II study of carboplatin, etoposide, and exisulind in patients with extensive small cell lung cancer: CALGB 30104.” J Thorac Oncol 4, no. 2 (February 2009): 220–26. https://doi.org/10.1097/JTO.0b013e3181951eb0.
       Full Text  Link to Item
    • Liptay, Michael J., Thomas A. D’amico, Chumy Nwogu, Todd L. Demmy, Xiaofei F. Wang, Lin Gu, Virginia R. Litle, Scott J. Swanson, Leslie J. Kohman, and Leslie J. Thoracic Surgery Subcommittee of the Cancer and Leukemia Group B. “Intraoperative sentinel node mapping with technitium-99 in lung cancer: results of CALGB 140203 multicenter phase II trial.” J Thorac Oncol 4, no. 2 (February 2009): 198–202. https://doi.org/10.1097/JTO.0b013e318194a2c3.
       Full Text  Link to Item
    • Miller, Antonius A., Xiaofei F. Wang, Lin Gu, Philip Hoffman, Jamil Khatri, Frank Dunphy, Martin J. Edelman, et al. “Phase II randomized study of dose-dense docetaxel and cisplatin every 2 weeks with pegfilgrastim and darbepoetin alfa with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (CALGB 30303).” J Thorac Oncol 3, no. 10 (October 2008): 1159–65. https://doi.org/10.1097/JTO.0b013e318186fb0d.
       Full Text  Link to Item
    • Socinski, Mark A., A William Blackstock, Jeffrey A. Bogart, Xiaofei Wang, Michael Munley, Julian Rosenman, Lin Gu, et al. “Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105.” J Clin Oncol 26, no. 15 (May 20, 2008): 2457–63. https://doi.org/10.1200/JCO.2007.14.7371.
       Full Text  Link to Item
    • Kratzke, Robert A., Xiaofei Wang, Long Wong, Marian G. Kratzke, Mark R. Green, Everett E. Vokes, Nicholas J. Vogelzang, Hedy L. Kindler, Jeffrey A. Kern, and Jeffrey A. Cancer and Leukemia Group B. “Response to the methylation inhibitor dihydro-5-azacytidine in mesothelioma is not associated with methylation of p16INK4a: results of cancer and leukemia group B 159904.” J Thorac Oncol 3, no. 4 (April 2008): 417–21. https://doi.org/10.1097/JTO.0b013e318168da0a.
       Full Text  Link to Item
    • Edelman, Martin J., Dee Watson, Xiaofei Wang, Carl Morrison, Robert A. Kratzke, Scott Jewell, Lydia Hodgson, et al. “Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203.” J Clin Oncol 26, no. 6 (February 20, 2008): 848–55. https://doi.org/10.1200/JCO.2007.13.8081.
       Full Text  Link to Item
    • Rudin, Charles M., Ravi Salgia, Xiaofei Wang, Lydia D. Hodgson, Gregory A. Masters, Mark Green, and Everett E. Vokes. “Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103.” J Clin Oncol 26, no. 6 (February 20, 2008): 870–76. https://doi.org/10.1200/JCO.2007.14.3461.
       Full Text  Link to Item
    • Graziano, Stephen L., James E. Herndon, Mark A. Socinski, Xiaofei Wang, Dorothy Watson, Everett Vokes, Mark R. Green, and Mark R. Cancer and Leukemia Group B. “Phase II trial of weekly dose-dense paclitaxel in extensive-stage small cell lung cancer: cancer and leukemia group B study 39901.” J Thorac Oncol 3, no. 2 (February 2008): 158–62. https://doi.org/10.1097/JTO.0b013e318161225e.
       Full Text  Link to Item
    • Graziano, Stephen L., Lin Gu, Xiaofei F. Wang, Arthur H. Tatum, Robin T. Vollmer, Gary M. Strauss, Robert A. Kratzke, Mark R. Green, and Everett E. Vokes. “D5-01: Prognostic significance of molecular markers and clinical factors in stage ib non-small cell lung cancer (NSCLC): a laboratory companion study to CALGB 9633.” Journal of Thoracic Oncology 2, no. 8 (August 2007): S403–S403. https://doi.org/10.1097/01.jto.0000283278.97704.03.
       Full Text
    • Miller, Antonius A., Xiaofei F. Wang, Jeffrey A. Bogart, Lydia D. Hodgson, Caio M. S. Rocha Lima, James E. Radford, Everett E. Vokes, Mark R. Green, and Mark R. Cancer and Leukemia Group B (CALGB). “Phase II trial of paclitaxel-topotecan-etoposide followed by consolidation chemoradiotherapy for limited-stage small cell lung cancer: CALGB 30002.” J Thorac Oncol 2, no. 7 (July 2007): 645–51. https://doi.org/10.1097/JTO.0b013e318074bbf5.
       Full Text  Link to Item
    • Perry, Michael C., Leslie J. Kohman, James A. Bonner, Lin Gu, Xiaofei Wang, Everett E. Vokes, and Mark R. Green. “A phase III study of surgical resection and paclitaxel/carboplatin chemotherapy with or without adjuvant radiation therapy for resected stage III non-small-cell lung cancer: Cancer and Leukemia Group B 9734.” Clin Lung Cancer 8, no. 4 (January 2007): 268–72. https://doi.org/10.3816/CLC.2007.n.005.
       Full Text  Link to Item
    • Wang, Xiaofei, and Haibo Zhou. “A semiparametric empirical likelihood method for biased sampling schemes with auxiliary covariates.” Biometrics 62, no. 4 (December 2006): 1149–60. https://doi.org/10.1111/j.1541-0420.2006.00612.x.
       Full Text  Link to Item
    • Riedel, Richard F., Xiaofei Wang, Meg McCormack, Eric Toloza, Gustavo S. Montana, Gilbert Schreiber, and Michael J. Kelley. “Impact of a multidisciplinary thoracic oncology clinic on the timeliness of care.” J Thorac Oncol 1, no. 7 (September 2006): 692–96.
       Link to Item
    • Pincus, T., X. Wang, C. Chung, T. Sokka, and G. G. Koch. “Erratum: Patient preference in a crossover clinical trial of patients with osteoarthritis of the knee or hip: Face validity of self-report questionnaire ratings (Journal of Rheumatology (2005) 32 (533-539)).” Journal of Rheumatology 32, no. 5 (May 1, 2005): 966.
    • Pincus, Theodore, Xiaofei Wang, Cecilia Chung, Tuulikki Sokka, and Gary G. Koch. “Patient preference in a crossover clinical trial of patients with osteoarthritis of the knee or hip: face validity of self-report questionnaire ratings.” J Rheumatol 32, no. 3 (March 2005): 533–39.
       Link to Item
    • Wang, Youfa, and Xiaofei Wang. “How do statistical properties influence findings of tracking (maintenance) in epidemiologic studies? An example of research in tracking of obesity.” Eur J Epidemiol 18, no. 11 (2003): 1037–45. https://doi.org/10.1023/a:1026196310041.
       Full Text  Link to Item
    • Wang, Youfa, and Xiaofei Wang. “Re: "Tracking of cardiovascular risk factors: the Tromsø Study, 1979, 1995".” Am J Epidemiol 155, no. 12 (June 15, 2002): 1144–45. https://doi.org/10.1093/aje/155.12.1144.
       Full Text  Link to Item
    • Pincus, T., G. G. Koch, T. Sokka, J. Lefkowith, F. Wolfe, J. M. Jordan, G. Luta, et al. “A randomized, double-blind, crossover clinical trial of diclofenac plus misoprostol versus acetaminophen in patients with osteoarthritis of the hip or knee.” Arthritis Rheum 44, no. 7 (July 2001): 1587–98. https://doi.org/10.1002/1529-0131(200107)44:7<1587::AID-ART282>3.0.CO;2-X.
       Full Text  Link to Item
    • Wang, X., and C. A. Burbeck. “Scaled medial axis representation: evidence from position discrimination task.” Vision Res 38, no. 13 (June 1998): 1947–59. https://doi.org/10.1016/s0042-6989(97)00299-x.
       Full Text  Link to Item
    • Wang, X. F., and C. A. Burbeck. “Enhanced position sensitivity at scaled medial loci.” Investigative Ophthalmology and Visual Science 37, no. 3 (February 15, 1996).

  • Book Sections

    • George, S. L., X. Wang, and H. Pang. “Preface,” xv, 2016. https://doi.org/10.1201/9781315371566.
       Full Text
    • George, S. L., X. Wang, and H. Pang. “Preface,” xv, 2016. https://doi.org/10.1201/9781315371566.
       Full Text
    • George, S. L., X. Wang, and H. Pang. “Preface,” xv, 2016. https://doi.org/10.1201/9781315371566.
       Full Text
    • George, Stephen, Xiaofei Wang, and Herbert Pang. “Endpoints for Cancer Clinical Trials.” In Cancer Clinical Trials: Current and Controversial Issues in Design and Analysis, edited by Stephen George, Xiaofei Wang, and Herbert Pang, 3–36. Chapman & Hall, 2016.
    • George, Stephen, Xiaofei Wang, and Herbert Pang. “Endpoints for Cancer Clinical Trials.” In Cancer Clinical Trials: Current and Controversial Issues in Design and Analysis, edited by Stephen George, Xiaofei Wang, and Herbert Pang, 3–36. Chapman & Hall, 2016.
    • George, S. L., and X. Wang. “Targeted clinical trials.” In Designs for Clinical Trials: Perspectives on Current Issues, 157–77, 2012. https://doi.org/10.1007/978-1-4614-0140-7_7.
       Full Text
    • George, S. L., and X. Wang. “Targeted clinical trials.” In Designs for Clinical Trials: Perspectives on Current Issues, 157–77, 2012. https://doi.org/10.1007/978-1-4614-0140-7_7.
       Full Text

  • Conference Papers

    • Clarke, Jeffrey Melson, Xiaofei F. Wang, Lin Gu, Marvaretta Miesha Stevenson, Tom Stinchcombe, Sundhar Ramalingam, Scott Joseph Antonia, et al. “Interim results from the OPTIMAL trial: A phase II clinical trial of combination nivolumab, ipilimumab, and taxane in patients with untreated metastatic non-small cell lung cancer (NSCLC).” In Journal of Clinical Oncology, Vol. 38, 2020.
       Link to Item
    • Ross, Helen J., Chen Hu, Kristin Ann Higgins, Salma K. Jabbour, David E. Kozono, Taofeek Kunle Owonikoko, Benjamin Movsas, et al. “NRG Oncology/Alliance LU005: A phase II/III randomized clinical trial of chemoradiation versus chemoradiation plus atezolizumab in limited stage small cell lung cancer.” In Journal of Clinical Oncology, Vol. 38, 2020.
       Link to Item
    • Ross, Helen J., David E. Kozono, James John Urbanic, Terence Marques Williams, Carter Dufrane, Ilze Bara, Mayank Gandhi, et al. “AFT-16: Phase II trial of atezolizumab before and after definitive chemoradiation (CRT) for unresectable stage III non-small cell lung cancer (NSCLC).” In Journal of Clinical Oncology, Vol. 38, 2020.
       Link to Item
    • Dudek, Arkadiusz Z., Xiaofei F. Wang, Lin Gu, Tom Stinchcombe, Robert Arthur Kratzke, Everett E. Vokes, and Hedy L. Kindler. “Randomized phase 2 study of maintenance pemetrexed (Pem) versus observation (Obs) for patients (pts) with malignant pleural mesothelioma (MPM) without progression after first-line chemotherapy: Cancer and Leukemia Group B (CALGB) 30901 (Alliance).” In Journal of Clinical Oncology, Vol. 37. AMER SOC CLINICAL ONCOLOGY, 2019.
       Link to Item
    • Hensing, Thomas A., Xiaofei F. Wang, Junheng Gao, Tom Stinchcombe, Michael V. Knopp, Arkadiusz Z. Dudek, Stephen L. Graziano, et al. “Randomized multicenter phase II trial evaluating the sequencing of PD-1 inhibition with pembrolizumab (P) and standard platinum-based chemotherapy (C) in patients (pts) with metastatic non-small cell lung cancer (NSCLC) (AFT-09).” In Journal of Clinical Oncology, Vol. 37. AMER SOC CLINICAL ONCOLOGY, 2019.
       Link to Item
    • Stinchcombe, Tom, Robert Charles Doebele, Xiaofei F. Wang, David E. Gerber, Leora Horn, and D Ross Camidge. “Preliminary results of single arm phase 2 trial of brigatinib in patients (pts) with progression disease (PD) after next-generation (NG) anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) in ALK plus non-small cell lung cancer (NSCLC).” In Journal of Clinical Oncology, Vol. 37. AMER SOC CLINICAL ONCOLOGY, 2019.
       Link to Item
    • Stinchcombe, T. E., P. A. Janne, X. Wang, E. M. Bertino, J. M. Weiss, L. Bazhenova, L. Gu, et al. “A randomized phase II trial of erlotinib or erlotinib and bevacizumab in patients with advanced EGFR mutant non-small cell lung cancer (NSCLC).” In Ann Oncol, 29 Suppl 8:viii522, 2018. https://doi.org/10.1093/annonc/mdy292.066.
       Full Text  Link to Item
    • Stinchcombe, T. E., W. Fan, S. E. Schild, E. E. Vokes, J. Bogart, Q. -. T. X. Le, C. R. Thomas, et al. “A pooled analysis of individual patient data (IPD) of concurrent chemoradiotherapy for limited-stage small cell lung cancer (LS-SCLC) in elderly compared to younger patients (pts) who participated in US National Cancer Institute cooperative group studies.” In Ann Oncol, 29 Suppl 8:viii597–98, 2018. https://doi.org/10.1093/annonc/mdy298.004.
       Full Text  Link to Item
    • Kinsey, Emily, Elizabeth Ajazi, Xiaofei F. Wang, Mary Ann Johnston, and Jeffrey Crawford. “The importance of body composition and physical function on overall survival (OS) in non-small cell lung cancer (NSCLC) patients receiving platinum based chemotherapy (PBCT).” In Journal of Clinical Oncology, 36:e21088–e21088. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.e21088.
       Full Text
    • Ross, Helen J., David E. Kozono, James John Urbanic, Terence Marques Williams, Carter Dufrane, Ilze Bara, Mayank Gandhi, et al. “Phase II trial of atezolizumab before and after definitive chemoradiation for unresectable stage III NSCLC.” In Journal of Clinical Oncology, 36:TPS8585–TPS8585. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.tps8585.
       Full Text
    • Wang, Ting, Xiaofei Wang, Haibo Zhou, Jianwen Cai, and Stephen L. George. “Biomarker stratified design enriched by auxiliary variables.” In Trials, Vol. 18. BIOMED CENTRAL LTD, 2017.
       Link to Item
    • Yi, John, Jeffrey Melson Clarke, Patrick Healy, Xiaofei F. Wang, Debra Shoemaker, Mark W. Onaitis, Chelsae Dumbauld, et al. “Immune profiling of circulating T cells and TILs following neoadjuvant ipilimumab and chemotherapy in non-small cell lung cancer (NSCLC).” In Journal of Clinical Oncology, 35:26–26. American Society of Clinical Oncology (ASCO), 2017. https://doi.org/10.1200/jco.2017.35.7_suppl.26.
       Full Text
    • Pang, Herbert, Kang Yan, Robert Kratzke, Thomas Stinchcombe, Jeffrey Crawford, Hedy Kindler, Everett Vokes, and Xiaofei Wang. “Prognostic Model for Mesothelioma Based on Cancer and Leukemia Group B (CALGB) Trials (Alliance).” In Journal of Thoracic Oncology, 12:S1367–S1367. ELSEVIER SCIENCE INC, 2017.
       Link to Item
    • Stinchcombe, Thomas, Ying Zhang, Everett Vokes, Joan Schiller, Jeffrey Bradley, Karen Kelly, Walter Curran, et al. “A Pooled Analysis Comparing the Outcomes of Elderly to Younger Patients on NCTN Trials of Concurrent CCRT for Stage 3 NSCLC.” In Journal of Thoracic Oncology, 12:S374–75. ELSEVIER SCIENCE INC, 2017.
       Link to Item
    • Wang, Xiaofei, Xiaowen Cao, Thomas Stinchcombe, Jeffrey Bradley, Alex Adjei, David R. Gandara, Suresh Ramalingam, Herbert Pang, Everett Vokes, and Jeffrey Crawford. “Predicting Risk of Chemotherapy-Induced Severe Neutropenia in Lung Patients: A Pooled Analysis of US Cooperative Group Trials.” In Journal of Thoracic Oncology, 12:S922–23. ELSEVIER SCIENCE INC, 2017.
       Link to Item
    • Stinchcombe, Tom, Ying J. Zhang, Everett E. Vokes, Joan H. Schiller, Jeffrey D. Bradley, Walter John Curran, Benjamin Movsas, et al. “A pooled analysis of concurrent chemoradiotherapy (CCRT) for patients with stage III non-small cell lung cancer (NSCLC) who participated in U.S. cooperative group trials: Comparing the outcomes of elderly to younger patients (pts).” In Journal of Clinical Oncology, 34:8508–8508. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.8508.
       Full Text
    • Yang, Chi-Fu Jeffrey, Derek Y. Chan, Babatunde Yerokun, Xiaofei F. Wang, Betty Caroline Tong, Thomas A. D’Amico, Mark W. Onaitis, Matthew G. Hartwig, Mark F. Berry, and David Harpole. “Surgery versus optimal medical management of early-stage small cell lung cancer.” In Journal of Clinical Oncology, 34:8511–8511. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.8511.
       Full Text
    • Edelman, Martin J., Xiaofei Wang, Lydia Hodgson, Richard T. Cheney, Maria Baggstrom, Thomas Sachdev, Ajeet Gajra, et al. “Abstract CT238: Phase III randomized, placebo controlled trial of COX-2 inhibition in addition to standard chemotherapy for advanced non-small cell lung cancer (NSCLC):CALGB 30801 (Alliance).” In Clinical Trials. American Association for Cancer Research, 2014. https://doi.org/10.1158/1538-7445.am2014-ct238.
       Full Text
    • Socinski, Mark A., Xiaofei F. Wang, Maria Quintos Baggstrom, Lin Gu, Thomas E. Stinchcombe, Martin J. Edelman, Sherman Baker JR, Heather Dorothy Mannuel, Jeffrey Crawford, and Everett E. Vokes. “Sunitinib (S) switch maintenance in advanced non-small cell lung cancer (NSCLC): An ALLIANCE (CALGB 30607), randomized, placebo-controlled phase III trial.” In Journal of Clinical Oncology, 32:8040–8040. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.8040.
       Full Text
    • Stinchcombe, Tom, Lynette M. Sholl, Xiaofei F. Wang, Lin Gu, Mark A. Socinski, Scott J. Rodig, Marzia Capelletti, et al. “An analysis of the prevalence of HER2 and KRAS mutations, and ALK rearrangements and clinical outcomes in Cancer and Leukemia Group B [CALGB (Alliance)] trial 30406 in advanced non-small cell lung cancer (NSCLC).” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013.
       Link to Item
    • Pang, Herbert, Lin Gu, William Richards, Jeffery Crawford, Mark Green, Everett Vokes, and Xiaofei Wang. “Abstract 4707: Validation of survival prognostic models for non-small-cell lung cancer instage- and age-specific groups.” In Clinical Research. American Association for Cancer Research, 2013. https://doi.org/10.1158/1538-7445.am2013-4707.
       Full Text
    • Heist, Rebecca Suk, Xiaofei F. Wang, Lydia Hodgson, Gregory Alan Otterson, Tom Stinchcombe, Everett E. Vokes, and Mark A. Socinski. “CALGB 30704: A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small cell lung cancer (NSCLC).” In Journal of Clinical Oncology, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012.
       Link to Item
    • Janne, Pasi A., Xiaofei F. Wang, Lee M. Krug, Lydia Hodgson, Everett E. Vokes, and Hedy L. Kindler. “Phase II trial of sorafenib (bay 43-9006) in malignant mesothelioma: CALGB 30307.” In Annals of Oncology, 17:216–17. OXFORD UNIV PRESS, 2006.
       Link to Item
• Teaching & Mentoring
• 

  Recent Courses

  • BIOSTAT 708: Clinical Trial Design and Analysis 2021
  • BIOSTAT 708: Clinical Trial Design and Analysis 2020
• Scholarly, Clinical, & Service Activities
• 

  Service to the Profession

  • Associate editor for Statistics in Biopharmaceutical Research (SBR). 2016  2016
  • Editorial board for Chinese Clinical Oncology (CCO). 2016  2016
  • Deputy statistical editor for Journal of Thoracic and Cardiovascular Surgery. 2014  2014
  • Director of Statistics for Alliance for Clinical Trials in Oncology, NCI/NCTN. 2014  2014

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.